BioCrossroads
BioCrossroads launches second seed fund
April 30, 2012
J.K. WallBioCrossroads Inc. has raised an $8.25 million seed fund in its second attempt to help startup life sciences companies grow
to the point where they can attract venture capital or a corporate funder.
MoreBioCrossroads has stoked state's life sciences industry, but challenges remain
February 11, 2012
J.K. WallIn the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies,
an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national
reports on life sciences.
MoreHealth care VC hits new Indiana low in 2011
February 6, 2012
J.K. WallIndiana companies landed just $14.1 million in venture funding last year, the lowest amount of capital flowing to the
state’s health care sector since BioEnterprises began tracking such deals in 2005.
MoreIndiana's medical device workforce will need skills upgrade
January 14, 2012
J.K. WallA new report by BioCrossroads says 53 percent of the 20,000 jobs in Indiana’s medical-device sector require no more
than a high school education.
MoreBioCrossroads seeds upstart medical device maker
October 20, 2011
Chris O'MalleyBioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company chaired by a former Eli Lilly and Co. executive
developing an absorbable stent.
MoreBiocrossroads lands $2.8 million Lilly Endowment grant
October 8, 2011
IBJ StaffThe advocate for the state's life sciences industry has now pulled in more than $25 million from the endowment.
MoreMore life sciences firms opt to launch products in Europe
July 30, 2011
Maria LaMagnaThe U.S. Food and Drug Administration's growing reputation for unpredictability is spurring some Indianapolis companies to
join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations
occurring in their backyards.
MoreIndiana life sciences leaders look toward the future
July 30, 2011
Chris O'MalleyFormer Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez
and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry
in Indiana to venture capital and Purdue's Discovery Park.
MoreTech district could boost Indianapolis' convention business
July 23, 2011
Scott OlsonThe Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
MoreReport: State's life science sector continues to grow
June 23, 2011
Chris O'MalleyA total of 220 life sciences startups have been launched in Indiana since 2004, or an average of 44 per year, according to
a new report from BioCrossroads that tracked the industry’s growth over the last eight years.
MoreLilly licenses Xigris rights to new biotech firm
May 23, 2011
J.K. WallEli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created
local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
MoreBISHOP: Warsaw's orthopedics whizzes will master biologics
May 14, 2011
Industry cluster in northern Indiana has adapted to every other change in health care, and will absorb tissue regeneration,
too.
MoreIndianapolis bio sector hopeful as venture firms cash out
April 30, 2011
Chris O'MalleyProfits flowing from earlier investments could mean more available capital, but firms continue to be selective in placing
their bets.
MoreMarcadia Biotech principals ponder next course
March 22, 2011
Chris O'MalleyMarcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
MoreFranciscan's electronic records rollout shows industry growth
February 23, 2011
J.K. WallFranciscan Alliance will spend more than $100 million over the next two years to install a common electronic medical record
system at its 13 hospitals and more than 165 physician practices. It’s a sign of the growth of the health information
technology industry in Indiana, which a new BioCrossroads report says generates $200 million a year in sales and is growing
at 8 percent annually.
MoreRoche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreIndiana Seed Fund makes 11th investment
December 23, 2010
IBJ StaffA $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development
stage.
MoreLilly Endowment gives $35M to start pharmacy school
December 20, 2010
J.K. WallManchester College will use money to launch the state's third program offering doctorates in pharmacy.
MoreState adds record number of life sciences jobs
December 11, 2010
IBJ StaffTwenty companies committed this year to add more than 4,000 jobs.
MoreIndiana life sciences upstarts tap health reform booty
November 6, 2010
IBJ StaffThe federal legislation is roundly criticized at a BioCrossroads meeting, but some firms have found a silver lining.
MoreIndiana's life sciences industry sees trouble ahead
October 30, 2010
Associated PressIndiana's life sciences industry has weathered the recession relatively well, but Eli Lilly's struggles and tight capital
markets could threaten the future.
MoreBioCrossroads helping laid-off life sciences workers land safely
October 30, 2010
Chris O'MalleyIndiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched
a website that aims to keep that talent in the state.
MoreIndiana life sciences sector copes with shrinking VC pool
October 30, 2010
Chris O\'malleyVenture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.
MoreEndocyte's $86M IPO plan a boon for Indiana, investors
August 28, 2010
Greg AndrewsVenture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
MoreIndiana Seed Fund nearing end of $6 million stash
June 5, 2010
Chris O'MalleyHaving invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
IBJ Featured Advertisers
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
graham. they are even better w/ roasted marshmallows and melted chocolate
Apparently ticket sales are slow too...mas emails have been sent by the speedway in a last ditch attempt to get place fans to come.
Garden Valley Veggie flavor Wheat Thins Toasted Chips. Don't judge until you try them, haters!
Doc, a few important errors in your statements:
(1) The developer is spending the CITY'S money (the city is paying for the cost of the garage), so the city can damn well insist on a quality design.
(2) The LAW requires the proposed building to comply with design standards, and insisting that people follow the law is not giving anyone the "run-around."
(3) A two-week delay to make some minimal aesthetic improvements is hardly a great imposition being imposed on the developer.
(4) If the developer would rather build a crappy building elsewhere with their own money, then they are welcome to pick up and do so.
(4) Indianapolis is a major city, not some podunk town that needs to spread its legs for any developer that throws the place a sideways glance. Indianapolis should insist on the best, not settle for junk. Accepting anything is not going to make Indianapolis grow any faster (not sure where you got that silly notion from), nor is Indianapolis a slow-growth city compared to similarly sized city's in the Midwest.
Alone. Or with cheese.